S&P 500
7,701.60
-0.20%
Dow Jones
53,269.60
-0.40%
Nasdaq 100
29,372.90
-0.41%
Russell 2000
3,026.65
-0.28%
FTSE 100
10,723.20
-0.30%
Nikkei 225
65,606.50
-0.91%

Investing

IMTX logo Immatics : IMTX

IMTX

Stock Data

$9.25

Change up

$0.16 (1.76%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Immatics N.V. is a pioneering biopharmaceutical firm based in Tübingen, Germany, dedicated to advancing the fight against cancer through innovative T cell redirecting immunotherapies. Specializing in the development of treatments for solid tumors, Immatics is working on a range of promising therapies, including adoptive cell therapies and TCR Bispecifics. Their diverse product pipeline features several candidates in various stages of clinical and preclinical development, aimed at harnessing the body's immune system to target and destroy cancer cells. Immatics collaborates with leading institutions like MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S to push the boundaries of cancer treatment.

All Immatics Articles

1 Article